Evidence map›Paper›PMID 28160049›Full record

ArticleJournal of molecular medicine (Berlin, Germany)2017

Prolylcarboxypeptidase deficiency is associated with increased blood pressure, glomerular lesions, and cardiac dysfunction independent of altered circulating and cardiac angiotensin II.

Christoph Maier, Ines Schadock, Philipp K Haber, Jan Wysocki, Minghao Ye, Yashpal Kanwar, Christopher A Flask, Xin Yu, Brian D Hoit, Gregory N Adams and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of molecular medicine (Berlin, Germany), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 46 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. COVID-19, vaccines and deficiency of ACEEuropean journal of internal medicine · 2022
    Review
  14. Review
  15. Review
  16. An update on ACE2 amplification and its therapeutic potential.Acta physiologica (Oxford, England) · 2021
    Review
  17. Role of the renin-angiotensin system in the development of severe COVID-19 in hypertensive patients.American journal of physiology. Lung cellular and molecular physiology · 2020
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 3 countries.

Christoph MaierDivision of Nephrology and Hypertension, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Ines SchadockMax Delbrück Center for Molecular Medicine, Berlin, Germany.
Philipp K HaberDivision of Nephrology and Hypertension, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Jan WysockiDivision of Nephrology and Hypertension, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Minghao YeDivision of Nephrology and Hypertension, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Yashpal KanwarDepartment of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Christopher A FlaskDepartment of Radiology, Case Western Reserve University, Cleveland, OH, USA.
Xin YuDepartment of Radiology, Case Western Reserve University, Cleveland, OH, USA.
Brian D HoitDepartment of Medicine, Division of Cardiology, University Hospitals Case Medical Center and Case Western Reserve University, Cleveland, OH, USA.
Gregory N AdamsDepartment of Medicine, Division of Hematology and Oncology, University Hospitals Case Medical Center and Case Western Reserve University, Cleveland, OH, USA.
Alvin H SchmaierDepartment of Medicine, Division of Hematology and Oncology, University Hospitals Case Medical Center and Case Western Reserve University, Cleveland, OH, USA.
Michael BaderCharité-Universitätsmedizin Berlin, Berlin, Germany.
Daniel BatlleDivision of Nephrology and Hypertension, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. d-batlle@northwestern.edu.
Case Western Reserve University · USNorthwestern University · USCharité - Universitätsmedizin Berlin · DEMax Delbrück Center · DEUniversidade Federal de Minas Gerais · BRUniversity Hospitals Cleveland Medical Center · US

Funding

Phenotypic characterization of nitric oxide regulation of cardiac function by MRIR01HL073315 · NHLBI · WASHINGTON UNIVERSITY · PI YU, XIN · 2004 to 2014
$3.4M
Structural Basis of Ventricular FunctionR01HL086935 · NHLBI · CASE WESTERN RESERVE UNIVERSITY · PI YU, XIN · 2007 to 2010
$1.8M
Strategies for ACE2 Amplification to Treat Diabetic Kidney DiseaseR01DK080089 · NIDDK · NORTHWESTERN UNIVERSITY AT CHICAGO · PI BATLLE, DANIEL · 2009 to 2012
$1.3M
NHLBI NIH HHS R01 HL073315NHLBI NIH HHS R01 HL086935NIDDK NIH HHS R01 DK080089
6 · The paper itself

Abstract

Prolylcarboxypeptidase (PRCP) is a carboxypeptidase that cleaves angiotensin II (AngII) forming Ang(1-7). The impact of genetic PRCP deficiency on AngII metabolism, blood pressure (BP), kidney histology, and cardiac phenotype was investigated in two lines of PRCP-deficient mice: KST302 derived in C57BL/6 background and GST090 derived in FVB/N background. The GST090 line had increased mean arterial pressure (MAP) (113.7 ± 2.07 vs. WT 105.0 ± 1.23 mmHg; p < 0.01) and left ventricular hypertrophy (LVH) (ratio of diastolic left ventricular posterior wall dimension to left ventricular diameter 0.239 ± 0.0163 vs. WT 0.193 ± 0.0049; p < 0.05). Mice in the KST302 line also had mild hypertension and LVH. Cardiac defects, increased glomerular size, and glomerular mesangial expansion were also observed. After infusion of AngII to mice in the KST302 line, both MAP and LVH increased, but the constitutive differences between the gene trap mice and controls were no longer observed. Plasma and cardiac AngII and Ang(1-7) were not significantly different between PRCP-deficient mice and controls. Thus, PRCP deficiency is associated with elevated blood pressure and cardiac alterations including LVH and cardiac defects independently of systemic or cardiac AngII and Ang(1-7). An ex vivo assay showed that recombinant PRCP, unlike recombinant ACE2, did not degrade AngII to form Ang(1-7) in plasma at pH 7.4. PRCP was localized in α-intercalated cells of the kidney collecting tubule. The low pH prevailing at this site and the acidic pH preference of PRCP suggest a role of this enzyme in regulating AngII degradation in the collecting tubule where this peptide increases sodium reabsorption and therfore BP. However, there are other potential mechanisms for increased BP in this model that need to be considered as well. PRCP converts AngII to Ang(1-7) but only at an acidic pH. Global PRCP deficiency causes heart and kidney alterations and a moderate rise in BP. PRCP is abundant in the kidney collecting tubules, where the prevailing pH is low. In collecting tubules, PRCP deficiency could result in impaired AngII degradation. Increased AngII at this nephron site stimulates Na reabsorption and increases BP. KEY MESSAGE: Prolylcarboxypeptidase (PRCP) converts AngII to Ang (1-7) but only at an acidic pH. Global PRCP deficiency causes heart and kidney alterations and a moderate rise in BP. PRCP is abundant in the kidney collecting tubules, where the prevailing pH is low. In collecting tubules, PRCP deficiency could result in impaired AngII degradation. Increased AngII at this nephron site stimulates Na reabsorption and increases BP.

Indexed as

Angiotensin IAngiotensin IIAnimalsBlood PressureCarboxypeptidasesKidneyKidney GlomerulusKidney Tubules, CollectingMaleMiceMice, Mutant StrainsMyocardiumPeptide FragmentsAngiotensin Iangiotensin I (1-7)Angiotensin IICarboxypeptidaseslysosomal Pro-X carboxypeptidasePeptide FragmentsAngiotensin IIBlood pressureCardiac dysfunctionGlomerular lesionsProlylcarboxypeptidase deficiency

Identifiers

PMID28160049
OpenAlexW2583773699

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.